Navidea Biopharmaceuticals Announces 2016 Annual Meeting Results
August 11 2016 - 5:00PM
Business Wire
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) today
announced the results of voting at its 2016 Annual Meeting of
Stockholders (the Annual Meeting) held August 11, 2016.
Approximately 70 percent of outstanding shares were represented at
the meeting.
At the Annual Meeting, Navidea’s stockholders:
- Elected Y. Michael Rice and Eric K.
Rowinsky, M.D. to the Navidea Board of Directors to serve for a
term of three years;
- Increased the authorized number of
shares of the Company from 205,000,000 to 305,000,000, consisting
of 300,000,000 shares of common stock, $.001 par value, and
5,000,000 shares of preferred stock, $.001 par value; and
- Ratified the appointment of Marcum LLP
to act as the Company’s independent registered public accounting
firm for 2016.
The final results are subject to verification by the independent
election inspectors and will be reported in a Form 8-K to be filed
by Navidea with the Securities and Exchange Commission in the next
few days.
Following the formal business portion of the Annual Meeting, Jed
Latkin, Interim Chief Operating Officer and Chief Financial
Officer, shared a few remarks with stockholders in attendance at
the Annual Meeting.
About Navidea
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a
biopharmaceutical company focused on the development and
commercialization of precision immunodiagnostic agents and
immunotherapeutics. Navidea is developing multiple
precision-targeted products and platforms including Manocept™ and
NAV4694 to help identify the sites and pathways of undetected
disease and enable better diagnostic accuracy, clinical
decision-making, targeted treatment and, ultimately, patient care.
Lymphoseek® (technetium Tc 99m tilmanocept) injection, Navidea’s
first commercial product from the Manocept platform, was approved
by the FDA in March 2013 and in Europe in November 2014. The
development activities of the Manocept immunotherapeutic platform
will be conducted by Navidea in conjunction with its subsidiary,
Macrophage Therapeutics. Navidea’s strategy is to deliver superior
growth and shareholder return by bringing to market novel products
and advancing the Company’s pipeline through global partnering and
commercialization efforts. For more information, please visit
www.navidea.com.
The Private Securities Litigation Reform Act of 1995 (the Act)
provides a safe harbor for forward-looking statements made by or on
behalf of the Company. Statements in this news release, which
relate to other than strictly historical facts, such as statements
about the Company’s plans and strategies, expectations for future
financial performance, new and existing products and technologies,
anticipated clinical and regulatory pathways, and markets for the
Company’s products are forward-looking statements within the
meaning of the Act. The words “believe,” “expect,” “anticipate,”
“estimate,” “project,” and similar expressions identify
forward-looking statements that speak only as of the date hereof.
Investors are cautioned that such statements involve risks and
uncertainties that could cause actual results to differ materially
from historical or anticipated results due to many factors
including, but not limited to, the Company’s continuing operating
losses, uncertainty of market acceptance of its products, our
ability to repay our debt, the outcome of the CRG litigation,
reliance on third party manufacturers, accumulated deficit, future
capital needs, uncertainty of capital funding, dependence on
limited product line and distribution channels, competition,
limited marketing and manufacturing experience, risks of
development of new products, regulatory risks and other risks
detailed in the Company’s most recent Annual Report on Form 10-K
and other Securities and Exchange Commission filings. The Company
undertakes no obligation to publicly update or revise any
forward-looking The Company undertakes no obligation to publicly
update or revise any forward-looking statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160811005865/en/
Navidea BiopharmaceuticalsInvestors &
MediaSharon Correia, 978-655-2686Senior Director, Corporate
Communications
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Sep 2023 to Sep 2024